

CURRICULUM VITAE

FRANCISCO A. MORENO, M.D.

Professor with Tenure, Psychiatry
Deputy Dean for Diversity and Inclusion
University of Arizona, College of Medicine
1501 N Campbell Avenue, Tucson, AZ 85724
•Telephone (520) 621-0235 • FAX (520) 626-6252 • E-mail:
fmoreno@email.arizona.edu

EDUCATION:

1/82 to 2/88 M.D. Autonomous University of Baja, California, School of
Medicine, Mexicali, México.

PROFESSIONAL CAREER:

Residency Training

7/92 - 6/96 University of Arizona and Affiliated Hospitals, Tucson, AZ
Psychiatry Residency (Research Track). Fully accredited
postgraduate specialty training, including a research track
experience.

7/95 - 6/96 Research track year. Full-time research training conducting
research activities and participating in graduate courses in
study design, statistical analysis, and use of software packages
for research design and data analysis.

7/96 - 6/97 University of Arizona Psychopharmacology Research Program,
Tucson, AZ. Fellowship in Neuropsychopharmacology.
Experience included subject recruitment, screening and rating,
protocol development, study progress and planning, data
analysis, interpretation and publication of results. Also
participated as principal investigator for pilot studies, and co-
investigator in several other new research projects, and as sub-
investigator in several pharmacological industry studies of
mood disorders, anxiety disorders, and schizophrenia.

Work Experience

7/88 - 2/90 Mental Health Clinician. Kino Community Hospital, doing
case management with psychiatric inpatients.

2/90 - 9/91 Mental Health Clinician. Arizona Center for Clinical
Management, doing case management with "Seriously

Mentally Ill” patients with special needs (medically ill, developmentally disabled, and elderly).

- 10/91 - 7/92 Psychiatric Clinical Specialist. Arizona Center for Clinical Management. Performing in a role similar to a physician’s assistant.
- 10/95 - 6/97 Independent Psychiatric Rating Examiner. Tucson’s Veteran Administration Medical Center. Examining veterans requesting compensation and pensions for psychiatric illnesses. (Moonlighting during residency)
- 7/96 - 3/97 Staff Psychiatrist. Southern Arizona Mental Health Corporation (SAMHAC). Providing outpatient services to the seriously mentally ill, and crisis intervention at the walk-in crisis center. (Moonlighting during residency)
- 3/97 - 6/97 Rural Psychiatrist. Southeastern Arizona Behavioral Health Services (SEABHS). Providing outpatient services to the seriously mentally ill and general mental health patients, and inpatient service on weekends. (Moonlighting during residency)
- 7/97 - 6/98 Research Assistant Professor. Medical Director and Attending Psychiatrist of Inpatient Psychiatry Unit, Investigator with the Psychopharmacology Research Program at The Arizona Health Sciences Center.
- 7/98 - 6/99 Assistant Professor of Psychiatry - Tenure Eligible Track, Director of Inpatient Psychiatry Unit; Investigator with the Psychopharmacology Research Program at The University of Arizona Department of Psychiatry.
- 7/99 - 06/04 Assistant Professor of Psychiatry - Tenure Eligible, Investigator with the Research Program in Psychiatry and Clinical Neuroscience at The University of Arizona Department of Psychiatry.
- 10/00 - 2/01 Interim Director of Residency Program in Psychiatry, Department of Psychiatry, University of Arizona, College of Medicine
- 11/00 - 3/02 Director of Psychopharmacology Research Program, Department of Psychiatry, University of Arizona, College of Medicine
- 2/01 - 2/05 Director of Residency Program in Psychiatry, Department of Psychiatry, University of Arizona, College of Medicine

07/04 - 6/10	Associate Professor of Psychiatry with Tenure, Department of Psychiatry, University of Arizona, College of Medicine
08/09 - 12/10	Associate Head, Department of Psychiatry, University of Arizona, College of Medicine
11/09 -	Interim Director, University Physicians Hospital Outpatient Psychiatry Clinic
07/10 -	Professor of Psychiatry with Tenure, Department of Psychiatry, University of Arizona, College of Medicine
1/11- 2/12	Interim Head, Department of Psychiatry, University of Arizona, College of Medicine
3/12 - 12/12	Executive Vice Chair, Department of Psychiatry, University of Arizona, College of Medicine
11/12 -	Deputy Dean for Diversity and Inclusion, University of Arizona, College of Medicine

LICENSURE AND CERTIFICATION:

1988	Medical license in México
1992	ECFMG certification
1995	Medical license in the state of Arizona
2000	Diplomat, American Board of Psychiatry and Neurology
2010	Renewal of ABPN Board Certification

HONORS AND AWARDS:

1984	Elected President of the Student Body, School of Medicine
1985	Awarded by the University of Baja California for Outstanding Representation of the School of Medicine as co-founder of the Coalition of Presidents of Student Bodies within the University of Baja California
1994 - 1995	Awarded the APA - Mead Johnson Fellowship
1995 - 1996	Chief Resident at the AHSC Department of Psychiatry
1995	Awarded as APA fellow to the Annual Meeting of the American College of Neuropsychopharmacology
1996	Awarded as APA fellow to the Annual Meeting of the APA
1996	Awarded the NIH / NIMH New Investigators' Award at the New Clinical Drug Evaluation Unit
1996 - 1997	Awarded an NIH/ National Research Service Award 1-year fellowship salary support through the APA's Program for Minority Research Training in Psychiatry
1997 - 1999	Awarded NIH R03 2-year Grant

1998 - 2000	Dean's Physician Scientist Career Development Award
2000	Diplomate, American Board of Psychiatry and Neurology
2001	Foreign Travel Award, Office of International Affairs, University of Arizona
2002	Research Career Development Fund Grant, Office of Academic Affairs, University of Arizona
2003- 2008	Awarded NIMH/ R01 grant
2004	Awarded Tenure and Associate Professor Status at The University of Arizona, College of Medicine, Dept of Psychiatry
2005 - 2006	Institute for Mental Health Research Pilot Grant Award
2005 - 2006	President Elect: West Coast College of Biological Psychiatry
2006 - 2007	President: West Coast College of Biological Psychiatry
2006	Training Director's Award for Outstanding Contribution to Residency Education (UMC Program)
2007 - 2008	Junior Resident's Award for Excellence in Psychiatric Education
2008 - 2010	Awarded Robert Wood Johnson Foundation Grant
2009	Honorary Chair for NAMI of Southern Arizona March, 2009
2010 -	Elected, Western Region Representative of American Association of Medical Colleges Group on Diversity and Inclusion
2009-2010	Junior Resident's Award for Excellence in Psychiatric Education
2010	Training Director's Award for Outstanding Contribution to Residency Education (UPH Program)

SERVICE:

Outreach:

1994	Member, Arizona Psychiatric Society
1994	Member, American Psychiatric Association
1995	Member, American Medical Association
1996	Member, Physicians for Human Rights
1997 – 2005	Member, Society for Neuroscience
1997 – 2005	Member, American Association for the Advancement of Science
1998	Member, American Society of Hispanic Psychiatry
1998 – 2011	Fellow, West Coast College of Biological Psychiatry
1999	Member, Tucson Psychiatric Society
2000	Member, Society of Biological Psychiatry
2000 – 2001	Member, Society for Promotion of European Neuroscience
2001- 2005	Member, American Association of Directors of Psychiatry Residency Training
2003	Elected Member, American College of Psychiatrists
2006 - 2007	President, West Coast College of Biological Psychiatry
2010 -	Elected Member, Psychiatric Research Society

Citizenship:

1997 - 1998 Instructor-Mentor, Professional Internship Program from Tucson Unified School District

1997 - 1998 Preceptor, Nurse practitioner Student Internship

1997 - 2005 Member, Psychiatry Medical Student Education Committee

1998 - Member, Psychiatry Residency Education and Progress Committee

1998 - Independent Psychiatric Evaluator for Victims of Human Rights Violations (Volunteer: Physicians for Human Rights)

1998 - 2001 Member of the University of Arizona Human Subjects Committee (Full time UA HSC).

2001 - 2003 Part time UA HSC (Alternate participant)

1999 - 2007 Interviewer, College of Medicine Admissions Committee

1997 - Interviewer, Psychiatry Residency Applicants and Selection Committee Participant

1999 - 2013 Departmental Review Chairman for Human Subjects Committee

2000 - 2003 Member of the American Psychiatric Association Subcommittee on Self-Assessment Examinations (PSA-R taskforce).

2000 - 2002 Coordinator, Department of Psychiatry Faculty Recruitment Committee.

2000 - 2000 Ad-Hoc grant reviewer, Netherlands Science Foundation

2000 - 2005 Member, University of Arizona Graduate Medical Education Committee

2001 - 2001 Member, Selection Committee for University of Arizona Director, Human Subjects Protection Program, and for College of Medicine Office of Research Biostatistical Consultant

2001 - Member Editorial Board, Journal of Clinical Psychiatry

2001 - 2004 Coordinator, Department of Psychiatry Education Committee

2001 - 2008 Ad-Hoc grant reviewer, Heffter Research Institute

2002 - 2003 Member, Scientific Advisory Board, Heffter Research Institute

2002 - 2003 Director, Continuous Medical Education, Arizona Psychiatric Society

2003 - 2005 Member of the American Psychiatric Association Journal "Focus" Advisory Board.

2004 - 2008 Arizona Hispanic Center of Excellence, Mentor

2004 - 2010 Ad-Hoc grant reviewer, National Institute of Mental Health

2004 Member, Internal Review Committee, Neurology Residency Program

2005 - 2008 Reviewer for the Arizona Alzheimer's Disease Core Center

2005 - 2010 Physician Advisor and regular speaker for local Depression Bipolar Support Alliance Chapter

2005 Ad Hoc Reviewer for NIMH B-START program

2005 - Member, Departmental Promotion and Tenure Committee

2006 - 2009 Member, APA/SAMHSA Selection and Advisory Corresponding Committee for the APA Minority Fellowships Program

2006 - 2009	Reviewer, American Institute of Biological Sciences
2006	Ad Hoc Advisor for NIMH DSMBs.
2006 - 2008	Member, NIMH Study Section F12B-J
2007 - 2012	Member, Faculty Advisory Committee, College of Medicine
2007 - 2010	Chairman, Faculty Diversity Committee, College of Medicine
2006 -	Interviewer for Office of Outreach and Multicultural Affairs - Annual Medical Mock Interview Workshop
2007 - 2009	Member. College of Medicine Promotion and Tenure Guidelines Design Committee
2008	Member, External Review Committee for Neurology Department
2008 - 2009	Reviewer, Arizona Clinical and Translational Research Clinical Scholar Proposals
2008 -	Advisor, Latino Medical Student Association of Arizona
2008 - 2012	UPH and U of A representative to the Behavioral Health Coalition of Southern Arizona
2008	National Alliance for the Mentally Ill of Southern Arizona, Honorary Chair of NAMI Walk 2009
2009 -	Board of Directors Member NAMI of Southern Arizona
2009 -	Member, Psychiatry Finance Committee
2009 - 2011	Member Executive Committee, UPH-H Provider Based Clinic
2010 - 2012	Member, American Association of Medical Colleges Steering Committee for Group on Diversity and Inclusion
2010 - 2012	Member, University Medical Center Pharmacy and Therapeutic Committee
2011 - 2012	Member, Faculty Practice Committee U. of Arizona COM
2011 - 2012	Member, Medical Executive Committee, UMC
2012 -	Member, Campus Diversity Coalition, U. of Arizona

Ad Hoc Journal Reviewer:

1997 -	Journal of Clinical Psychiatry
1999 - 2010	Journal of Psychopharmacology
1999 - 2009	Journal of Pharmacology, Biochemistry and Behavior
2000 -	Journal of Biological Psychiatry
2000 -	International Journal of Neuropsychopharmacology
2001 -	Neuropsychopharmacology Journal
2001 - 2011	Life Sciences Journal
2002 -	Molecular Psychiatry Journal
2002 - 2003	Pakistani Journal of Physicians and Surgeons
2003 - 2011	General Hospital Psychiatry
2004 -	Archives of General Psychiatry
2004 -	American Journal of Psychiatry
2004 - 2009	American Journal of Geriatric Psychiatry
2005 - 2008	Journal of Neural Transmission
2005 - 2006	American Journal of Medicine
2005 - 2007	Neuropsychiatric Genetics
2006 - 2009	CNS Spectrums
2006 - 2008	Comprehensive Psychiatry

2006 - 2009	American Journal of Geriatric Psychiatry
2007 - 2009	Neuroscience Letters
2008 - 2012	BioMed Central

Teaching / Education / Mentoring:

Courses and Seminars:

1997 - 2001	Developer and Coordinator, Inpatient Psychiatry and Psychopharmacology Courses for Psychiatry PGY-1s.
1997 - 2001	Coordinator, Psychopharmacology Course for PGY-1s.
1997 - 2008	Depression and Anxiety in the Medical Setting Seminar for PGY-2s
1997 - 2008	Depression Seminar for Inpatient Psychiatry Course
1997 - 2008	Introduction to Psychopharmacology, Seminar for PGY-1s
1997 - 2007	ECT, Seminar for PGY-1s
1997 - 2008	Antidepressants, Seminar for PGY-1s
1998 - 2008	Psychopathology of Depression, Seminar for PGY-2s
1998 - 2008	Psychopharmacology Overview, Seminar for PGY2s
1998 - 2008	Antidepressants, Parts I and II Seminar for PGY-2s
1998 - 2001	Electroconvulsive Therapy Seminar for each Medical Students rotation
1998 - 2001, 2005	Electroconvulsive Therapy Seminars for Residents.
2000 -	Neurochemistry, Seminar for PGY-4s and Child Fellows
2000 -	Biology of Affective Disorders, Seminar for PGY-4s
2000 - 2008	Coordinator, Psychopharmacology Course PGY-2s
2000 - 2008	Coordinator, Advanced Psychopharmacology Course PGY-4s
2001 - 2006	Coordinator, Leaving Residency Course PGY-4s
2001 - 2007	Risk of Depression, Seminar for PGY-4s
2001 - 2009	OCD, Seminar for PGY-4s
2002 - 2009	Treatment Refractory Depression, Seminar for PGY-4s
2002 - 2009	Electrical Stimulation in Psychiatry, Seminar for PGY-4s
2004 -	Developer/Instructor, Integrated Psychopharmacology Course Series for PGY-3&4 (Year long, every other year)
2009 -	Instructor of year six month long Psychopharmacology Course (PGY1 and 2 every other year)
2009 - 2013	Director, Annual Psychopharmacology Review Course, Sponsored by The University of Arizona
2010 -	Medical Student Seminars on Schizophrenia, Depression, Mood Disorders (three hours every six week rotation)

Preceptorships:

1997 - 2012	Supervision of Medical Students and Residents in Research Electives.
1997 - 1998	Instructor-Mentor, Professional Internship Program from Tucson Unified School District
1998 - 1998	Preceptor, Nurse practitioner Student Internship, University of Arizona
2001 - 2011	Mentor, Summer Institute in Medical Ignorance, COM, University of Arizona

2006 - 2008 Mentor, McNair Graduate Research Program, University of Arizona

Clinical Supervision:

1997 - 2000 Inpatient Service Clinical Supervision of two PGY-2 Psychiatry Residents, and two Medical Students in Rotation
1998 - 2013 Psychiatry Residents (four to seven), individually, one hour /week each. Department of Psychiatry, University of Arizona
2000 - 2005 Supervision of Psychiatry Chief Residents for clinical-educational administration

Mentoring experience:

1998 - 1999 Tracy Michaels, M.D., Attending Psychiatrist of the Inpatient Psychiatric Unit
2001 - 2002 Adam Opbroek, M.D., PGY-IV-Research Track Year
2001 - 2002 Josette Weibrecht, M.D., Research Fellowship Year
2001 - 2002 Damian Parkinson, M.D., Research Collaboration MS-IV, PGY-I
2001 - 2003 Christopher B. Wiegand, M.D., PGY-IV-Research Track Year
2003 - Steve Herron, M.D., Associate Residency Director, then Residency Director
2003 - 2006 Holly Garriock, Ph.D., Graduate Research Advisor
2006 - 2007 Mary Adde, Graduate Research Advisor
2006 - 2009 Crysta Clemente, Undergraduate Mentor (2006-2007) and Medical School Summer Research Program Mentor (2009)
2008 - 2009 Sara Williamson, Undergraduate Honors Program Mentor
2008 - 2009 Katherine Ovsevit, MPH, Graduate Thesis Advisor
2007 - 2009 Andrew Bismark, Graduate Research Advisor

Graduate and Ph.D. Committees:

2003 - 2006 Holly Garriock, Ph.D., Genetics Graduate Interdisciplinary Program
2006 - 2007 Mary Adde, Graduate Interdisciplinary Program in Genetics
2007 - Andrew Bismark, Psychology

PUBLICATIONS:

Book Chapters:

1. **Moreno FA**, Delgado PL, Gelenberg AJ. (1996) Maintenance treatment of bipolar disorder, in D. Dunner (Ed.) Current Psychiatric Therapy II. Book chapter #38; 271-282.
2. Delgado PL, **Moreno FA**, Potter RL, Gelenberg AJ. (1997) Norepinephrine and serotonin in antidepressant action, in Briley and Montgomery (Ed.) Antidepressant Therapy. Book chapter #8; 141-161.

3. Rotenberg SL, **Moreno FA**. (2004) Depresiones: Una introducción a su estudio y tratamiento, in Alarcón, Mazzotti, & Nicolini (Ed.) *Psiquiatría*.
4. Delgado PL, **Moreno FA**. (2005) Neurochemistry of Mood Disorders. The American Psychiatric Publishing Textbook of Mood Disorders. Book Chapter #6; 101-116.
5. **Moreno FA***, Garriock H. (2006) Depression and Genetics, in Schwartz and Petersen (Ed.) *Depression: Treatment Strategies and Management*. Book Chapter #8. 217-227.
6. **Moreno FA**, Delgado PL. (2007) Psilocybin Treatment of Obsessive Compulsive Disorder, in Winkelman and Roberts (Ed.) *Psychedelic Medicine: Social, Clinical, and Legal Perspectives*. Book Chapter #6; 135-149.
7. **Moreno FA**, Garriock H. (2009) Depression and Genetics, in Schwartz and Petersen (Ed.) *Depression: Treatment Strategies and Management*. Book Chapter.
8. **Moreno FA**, Heron S. (2009) Treatment of The Uninsured Mentally Ill, in Johnson and Johnson (Ed.) by Springer Publishing. *Treatment of The Underserved*. Book Chapter.

Journal Articles:

9. Delgado PL, Gelenberg AJ, **Moreno FA**, Laukes CA, Strayer LJ. (1996) Tryptophan and 5-HT in psychiatric illness. *Advances in Experimental Medicine & Biology*. 398:73.
10. **Moreno FA**, Gelenberg AJ, Bachar K, Delgado PL. (1997) Pindolol augmentation of antidepressant action: A double blind placebo controlled trial of pindolol augmentation in treatment of refractory depressed patients. *J Clinical Psychiatry*, 58(10): 437-439.
11. **Moreno FA**, Delgado PL, Gelenberg AJ. (1997) Hallucinogen-Induced Relief of Obsessions and Compulsions. *Letters to the Editor*. *Am J Psychiatry*, 154(7): 1037-1038.
12. Delgado PL, **Moreno FA**. (1998) Different roles for serotonin in anti-obsessional drug action and the pathophysiology of obsessive-compulsive disorder. *B J Psychiatry*, 173 (suppl. 35): 21-25.
13. Delgado PL, **Moreno FA**. (1998) Hallucinogens, serotonin and obsessive-compulsive disorder. *Journal of Psychoactive Drugs*, 30 (4): 359-366.
14. Delgado PL, Miller HM, Salomon RM, Licinio J, Krystal JH, **Moreno FA**, Heninger GR, Charney DS. (1999) Tryptophan depletion challenge in depressed patients treated with desipramine or fluoxetine: Implications for the role of serotonin in the mechanism of antidepressant action. *Biol Psychiatry*, 46:212-220.

15. **Moreno FA**, Gelenberg AJ, Heninger GR, Potter RL, McKnight KM, Allen J, Phillips AP, Delgado PL. (1999) Tryptophan depletion and depressive vulnerability. Biol Psychiatry, 46(4): 498-505.
16. Delgado PL, McGahuey CA, **Moreno FA**, Laukes C, Gelenberg AJ (1999) Treatment strategies for depression and sexual dysfunction. J Clin Psychiatry Monograph Series 17(1): 15-21.
17. Delgado PL, **Moreno FA**. (1999) Antidepressants and the brain. Int Clin Psychopharmacol, 14(suppl. 1):S9-S16.
18. McGahuey CA, Gelenberg AJ, Laukes CA, McKnight KM, Manber R, **Moreno FA**, Delgado PL. (2000) The Arizona Sexual Experiences Scale (ASEX): Reliability and validity. J Sex Marital Therapy, 26:25-40.
19. Delgado, PL, **Moreno, FA**. (2000) Role of Norepinephrine in depression. J Clin Psychiatry 61 (suppl 1): 5-12.
20. Gelenberg AJ, Laukes C, McGahuey C, Okayli G, **Moreno F**, Zentner L, and Delgado P. (2000). Mirtazapine substitution in SSRI-induced sexual dysfunction. J Clin Psychiatry 61 (5): 356-360.
21. **Moreno FA**, Heninger GR, McGahuey CA, Delgado PL. (2000). Tryptophan depletion and risk of depression relapse: A prospective study of TRP depletion as a potential predictor of depressive episodes. Biol Psychiatry; 48: 327-329.
22. **Moreno, FA**, Delgado PL. Living with anxiety disorders: As good as it gets...? (2000). Bulletin of the Menninger Clinic; 64 (3) Supplement A: A4-A21.
23. **Moreno, FA**, McGavin C, Malan TP, Gelenberg AJ, Heninger GR, Mathe AA, Delgado, PL. (2000). Tryptophan depletion selectively reduces CSF5-HT metabolites in healthy young men: Results from single lumbar puncture sampling technique. IJNP; 3 (4) 277-283.
24. **Moreno FA**, Rowe DC, Kaiser B, Chase D, Michaels T, Gelernter J, Delgado PL. (2002). Association between a serotonin transporter promoter region polymorphism and mood response during tryptophan depletion. Molecular Psychiatry; 7 (2): 213-216.
25. Delgado PL, **Moreno FA**, Laukes C, McGahuey C, Okayli G, Zentner L, and Gelenberg AJ. (2002) Sequential Depletion of Monoamines in Mirtazapine Treated Patients. Int J Neuropsychopharmacol; 5 (1): 63-66.
26. Opbroek A, Delgado PL, Laukes C, McGahuey C, Katsanis J, **Moreno FA**, and Manber R. (2002). Emotional blunting associated with SSRI-induced sexual dysfunction: Do SSRI's inhibit emotional responses? Int J Neuropsychopharmacol. Jun; 5 (2): 147-51.

27. **Moreno FA**, Weibrecht J, and Delgado PL. (2002). Novel Approaches to the Study of Vulnerability to Depression. *Essential Psychopharmacology*; 5(2): 99-115.
28. **Moreno FA**, and Delgado PL. (2004). A genetic polymorphism within the serotonin transporter gene and response tryptophan depletion. *Primary Psychiatry*; 11(6): 48-51.
29. Carpenter LL, **Moreno FA**, Kling MA, Anderson GM, Regenold WT, Labiner DM, and Price LH. (2004) Effect of Vagus Nerve Stimulation on CSF Monoamine Metabolites, Norepinephrine, and GABA Concentrations in Depressed Patients. *Journal of Biological Psychiatry*; 56 (6): 418-426.
30. **Moreno FA**, Macey H, Schreiber B. (2005) Carnitine levels in psychiatric patients treated chronically with valproic acid. *Journal of Clinical Psychiatry*; 66 (5): 555-558
31. Rush AJ, Sackeim HA, Marangell LB, George M, Brannan S, Davis S, Lavori P, Howland R, Kling M, Rittberg B, Carpenter L, Ninan P, **Moreno FA**, Schwartz T, Conway C, Burke M, Barry J. (2005) Effects of 12 Months of Vagus Nerve Stimulation in Treatment-Resistant Depression: A Naturalistic Study. *Biological Psychiatry*; 58:355-363.
32. George MS, Rush AJ, Marangell LB, Sackeim HA, Brannan S, Davis S, Lavori P, Howland R, Kling M, **Moreno FA**, Rittberg BR, Dunner D, Schwartz T, Carpenter L, Burke M, Ninan P, Goodnick P. (2005) A one-year comparison of vagus nerve stimulation (VNS) with treatment as usual for treatment resistant depression. *Biological Psychiatry*; 58:364-373.
33. Garriock HA, Allen JJB, Delgado P, Nahaz Z, Kling MA, Carpenter L, Burke M, Burke W, Schwartz T, Marangell LB, Husain M, Erickson RP, and **Moreno FA**. (2005) Lack of Association of TPH2 Exon XI polymorphism with Major Depression. *Molecular Psychiatry*; 10:976-977.
34. Garriock HA, Delgado P, Kling MA, Carpenter L, Burke M, Burke W, Schwartz T, Marangell LB, Husain M, Erickson RP, and **Moreno FA**. (2006) Number of risk genotypes is a risk factor for major depressive disorder: a case control study. *Behav Brain Funct.* 2 (1); 24.
35. **Moreno FA**, McGahuey C, Freeman M, Delgado PL. (2006). Gender Effects in Mood during Monoamine Depletion. *Journal of Clinical Psychiatry*; 67: 1618-1623.
36. Allen JJB, Schnyer RN, Chambers AS, Hitt SK, **Moreno FA**, Manber R. (2006). Acupuncture for Depression: A Controlled Trial. *Journal of Clinical Psychiatry*; 67: 1665-1673

37. **Moreno FA**, Wiegand C, Taitano K, Delgado PL. (2006). Safety, Tolerability, and Efficacy of psilocybin in 9 Patients with Obsessive Compulsive Disorder. *Journal of Clinical Psychiatry*; 67: 1735-1740
38. **Moreno FA**. Treatment Resistant Depression: The Role of Gene Factors. (2007) *Psychiatric Times*; 9: 21-24.
39. Schnyer RN, Chambers AS, Hitt SK, **Moreno FA**, Manber R, and Allen JJB. (2007). Acupuncture for major depressive disorder: Has its efficacy been disproved. Reply. *Journal of Clinical Psychiatry*; 68: 1617-1618.
40. Carpenter LL, Bayat L, **Moreno FA**, Kling MA, Price LH, Kinkead B, Owens MJ, Nemeroff CB. (2008) Decreased Cerebrospinal Fluid Concentrations of Substance P in Treatment Resistant Depression and Lack of Alterations after Acute Adjunct Vagus Nerve Stimulation Therapy. *Psychiatry Research*; Jan 15;157(1-3):123-9.
41. Freeman MP, Nolan PE, Davis MF, Anthony M, Fried K, Fankhauser M, Woosley RL, & **Moreno FA**. (2008). The Pharmacokinetics of Sertraline Across Pregnancy And Postpartum. *Journal of Clinical Psychopharmacology*; 28 (6): 646-653.
42. Allen JJB, McKnight KM, **Moreno FA**, Demaree HA, Delgado PL. (2009). Alteration of Frontal EEG Asymmetry during Tryptophan Depletion Predicts Future Depression. *Journal of Affective Disorders*; 115 (1-2):189-195.
43. Frank MJ, Doll BB, Oas-Terpstra J, & **Moreno FA**. (2009). Prefrontal and striatal dopaminergic genes predict individual differences in exploration and exploitation. *Nature Neuroscience*; 12 (8):1062-1068.
44. Chong J, Reinschmidt KM, and **Moreno FA**. (2010). Depression Symptoms in a Hispanic Primary Care Population with and without Chronic Illnesses. *Prim Care Companion J Clin Psychiatry*. 2010;12(3)
45. **Moreno FA**, Parkinson D, Palmer C, Castro WL, Misiaszek J, El-Khoury A, Mathe A, and Delgado PL. (2010). CSF Neurochemicals during Tryptophan Depletion in Remitted Depressive Subjects and Healthy Controls. *European Journal of Neuropsychopharmacology*; 20: 18-24.
46. Bismark AW, **Moreno FA**, Stewart JL, Towers DN, Coan JA, Oas J, Erickson RP, & JJB Allen. (2010). Polymorphisms of the HTR1a Allele are linked to Frontal Brain Electrical Asymmetry. *Biol Psychol*, 83(2):153-158.
47. Breitborde NJK, **Moreno FA**, Mai-Dixon N, Peterson R, Durst L, Bernstein B, Byreddy S, and McFarlane WR. (2011). Multifamily Group Psychoeducation and Cognitive Remediation for First-Episode Psychosis: A Randomized Controlled Trial. *BMC Psychiatry*; 11: 9

48. Garriock HA, **Moreno FA**. Genetics of Depression: Implications for Clinical Practice Yet? (2011). *Clinical Neuropsychiatry*; 8 (1) 37-46.
49. Howe GW, Gedzior AP, Weihs K, **Moreno FA**, Neiderhiser J. Higher-Order Structure in the Trajectories of Depression and Anxiety Following Sudden Involuntary Unemployment. (2012). *Journal of Abnormal Psychology*; 121(2): 325-338.
50. Chong J, and **Moreno FA**. Feasibility and Acceptability of Clinic-Based Telepsychiatry for Low-Income Hispanic Primary Care Patients. (2012). *Telemedicine and e-Health*; 18 (4): 297-304.
51. **Moreno FA**, Chong J, Dumbauld J, Humke M, and Byreddy S. Use of Standard Webcam and Internet Equipment for Telepsychiatry Treatment of Depression in Underserved Hispanics. (2012). *Psychiatric Services*; 63 (12): 1213-1217
52. Olin B, Jayewardene K, Bunker M, and **Moreno F**. Mortality and Suicide Risk in Treatment-Resistant Depression: An Observational Study of the Long-Term Impact of Intervention. New Research Article. (2012). *PLoS One.*;7(10). [Epub 2012 Oct 25.](#)
53. Aaronson ST, Carpenter LL, Conway C, Reimherr F, Lisanby SH, Schwartz TL, **Moreno FA**, Dunner D, Lesem M, Thompson PM, Husain M, Vine C, Banov M, Bernstein L, Lehman R, Brannon GE, Keepers GA, O'Reardon J, Rudolph R, Bunker M. Vagus Nerve Stimulation Therapy Randomized to Different Amounts of Electrical Charge for Treatment-Resistant Depression: Acute and Chronic Effects. *Brain Stimulation*, [Epub Ahead of Print Oct 2012.](#)
54. **Moreno FA**. Temporary Resolution of Tourette's Disorder Symptoms Following Psychedelic Drug Use. *Letters to the Editor*. [In Preparation](#)
55. **Moreno FA**, Garriock HA, Oas-Terpstra J, Erickson RP, & Delgado P. Exploration of Genetic Moderation of Depressive Response During Tryptophan Depletion in Medication-Free Subjects Remitted from Major Depression. [In Preparation](#)
56. Clemente CJ, Wiegand CB, Delgado PL, **Moreno FA**. The Relationship of Psilocybin Dose and Hallucinogenic Effects in a Controlled Medical Setting. [In Preparation](#)
57. **Moreno FA**. Suicidality in Treatment Resistant Depressives: Results form a 24-month Trial of Vagus Nerve Stimulation. [In Preparation](#)
58. **Moreno FA**, Freeman MP, Nolan PE, Davis MF, Anthony M, Fried K, Fankhauser M, & Woosley RL. Cytochrome P450 Genes and Effects on Pharmacokinetics of Sertraline Across Pregnancy. [In Preparation](#)

SELECTED PRESENTATIONS:

“Tryptophan Depletion and Vulnerability to Depression” Poster presented at the American Psychiatric Association Annual Meeting, May 1995, Miami, FL.

“Treatment of Undocumented Immigrants” Poster presented at the APA/Institute of Psychiatric Services, October 1995, Boston, MA.

“Mood Response to Tryptophan Depletion and Vulnerability to Depression” Poster presented at the Society of Neuroscience Meeting, November 1995, San Diego, CA.

“Tryptophan Depletion and Vulnerability to Depression” Poster presented at the American College of Neuropsychopharmacology Annual Meeting, December 1995, San Juan, Puerto Rico.

“Pindolol Augmentation of Antidepressant Action” Poster presented at the New Clinical Drug Evaluation Unit Annual Meeting, May 1996, Boca Raton, FL.

“Tryptophan Depletion: A Potential Predictor of Depressive Episodes” Poster presented at the American Psychiatric Association Annual Meeting, May 1996, New York, NY.

“Tryptophan depletion: A Potential Predictor of Depressive Episodes” Poster presented at the Annual Meeting of the Society for Neuroscience, November 1996, Washington, DC.

“Tryptophan depletion: A Potential Predictor of Depressive Episodes” Poster presented at the American College of Neuropsychopharmacology Annual Meeting, December 1996, San Juan, Puerto Rico.

“Obsessive Compulsive Spectrum Disorder” conference series sponsored by Solvay Pharmaceuticals, June 1997. Salt Lake City, UT; Kansas City, KS; Tucson, AZ; Phoenix, AZ; El Paso, TX; Albuquerque, NM.

“CSF Monoamine Metabolites During Tryptophan Depletion” Poster presentation at the American College of Neuropsychopharmacology Annual Meeting, December 1997, Kona, HI.

“Mirtazapine Substitution in Patients With Sexual Induced Sexual Dysfunction” Poster presentation at the Biological Psychiatry Annual Meeting, May 1998, Toronto, Canada.

“CSF Monoamine Metabolites During Tryptophan Depletion in Healthy Males” Poster presentation at the American Psychiatric Association Annual Meeting, June 1998, Toronto, Canada.

“Sequential Depletion of Monoamines in Mirtazapine Treated Patients” Poster presentation at the NCDEU Annual Meeting, May 1998, Boca Raton, FL.

- “Gender Differences in Mood during Tryptophan Depletion”*. Poster presentation at the American College of Neuropsychopharmacology Annual Meeting, December 1998, Las Croabas, Puerto Rico.
- “Gender Differences in Mood during Tryptophan Depletion”*. Poster presentation at the Annual Meeting of the West Coast College of Biological Psychiatry, April 1999, Tucson, Arizona.
- “Gender Differences in Mood during Tryptophan Depletion”*. Poster presentation at the Annual Meeting of NCDEU, June 1999, Boca Raton, Florida.
- “Gender Differences in Mood during Tryptophan Depletion”*. Poster presentation at the Society for Neuroscience Annual Meeting, October 1999, Miami, Florida.
- “Legacy and Promise of the Neurotransmitter Depletion Paradigm”*. Audiovisual presentation at the Annual Meeting of the American Society of Hispanic Psychiatrist, November 1999, Santa Fe, New Mexico.
- “Lack of Gender Effect During Catecholamine Depletion”*. Poster Presentation at the American College of Neuropsychopharmacology Annual Meeting, December 1999. Acapulco, Mexico.
- “Gender Effects During Monoamine Depletions.”* Audiovisual Presentation at the West Coast College of Biological Psychiatry Annual Meeting, April 2000, La Jolla, California.
- “Neurobiology of PTSD.”* Audiovisual Presentation at the American Society of Hispanic Psychiatry Annual Meeting, May 2000, Chicago, Illinois.
- “Lack of Gender Effect During Catecholamine Depletion.”* Poster Presentation at the American Psychiatric Association Annual Meeting, May 2000, Chicago, Illinois.
- “Transient nutritional depletion of monoamine precursors, biochemical and mood effects”* Audiovisual Presentation at International Symposium in Nutrients and Mood, November 2000, Strasbourg, France.
- “Association between SLC6A4 polymorphism and mood response to tryptophan depletion”*. Poster presentation at the American College of Neuropsychopharmacology Annual Meeting, December 2000, San Juan, Puerto Rico.
- “Genetic therapies in psychiatry”*. 9th Annual Psychopharmacology Review Conference, February 2001, Tucson, Arizona.
- “Vagal nerve stimulation in treatment resistant depression”*. 9th Annual Psychopharmacology Review Conference, February 2001, Tucson, Arizona.

- “Association between SLC6A4 polymorphism and mood response to tryptophan depletion”*. Audiovisual presentation at the Annual European Winter Conference on Brain Research, March 2001, Les Arc, France.
- “Genetic studies of neurotransmitter depletion paradigms”*. Audiovisual Presentation at the NCDEU Annual Meeting, May 2001, Phoenix, Arizona.
- “Genetic therapies for psychiatric disorders: Research and Ethical Issues”*. Audiovisual Presentation at the 10th Annual Psychopharmacology Review Conference, February 2002, Tucson, Arizona.
- “Frontier Research on Electrically Based Interventions in Psychiatric Treatment”*. Audiovisual Presentation at the 10th Annual Psychopharmacology Review Conference, February 2002, Tucson, Arizona.
- “Novel Approached to Treatment Resistant Depression”*. Audiovisual Presentation at the Annual Meeting of the Alaskan Psychiatric Association. April 2002, Anchorage, Alaska.
- “Supervision 101: Sex, lies, and videotape”*. Audiovisual Presentation at the Annual Meeting of the American Psychiatric Association. May 2002, Philadelphia, Pennsylvania.
- “Fear: Neurobiology and Treatment”*. Industry Sponsored Symposium, Audiovisual Presentation at the Annual Meeting of the American Psychiatric Association. May 2002, Philadelphia, Pennsylvania.
- “Treatment Refractory Depression”*. Audiovisual Presentation at the Annual Meeting of the Latin American Psychiatric Association. July 2002, Guatemala City, Guatemala.
- “New Research in Treatment Resistant Mood and Anxiety Disorders”*. Audiovisual Presentation at the Fall Scientific Conference of the Arizona Psychiatric Society. September, 2002, Tucson, Arizona.
- “Gender Differences in Mood and Anxiety”* Audiovisual Presentation at the University of Arizona Annual Women’s Mental Health Symposium. January, 2003, Tucson, Arizona.
- “Genetic therapies for psychiatric disorders: Research and Ethical Issues”*. Audiovisual Presentation at the 11th Annual Psychopharmacology Review Conference, February 2003, Tucson, Arizona.
- “Frontier Research on Electrically Based Interventions in Psychiatric Treatment”*. Audiovisual Presentation at the 11th Annual Psychopharmacology Review Conference, February 2003, Tucson, Arizona.

“The Genetic Basis of Neurobehavioral Phenotypes: Methods, applications, and controversies”. Audiovisual Presentation at the 72nd Annual Meeting of the American Academy of Physical Anthropology, April 2003, Tempe, Arizona.

“Safety, tolerability, and Efficacy of Psilocybin in Patients with Treatment Resistant Obsessive-compulsive Disorder” Poster presentation at the Biological Psychiatry Annual Meeting, May 2003, San Francisco, California.

“Safety, tolerability, and Efficacy of Psilocybin in Patients with Treatment Resistant Obsessive-compulsive Disorder” Poster presentation at the Annual Meeting of the American College of Neuropsychopharmacology, Dec 2003, San Juan, Puerto Rico.

“Vulnerability to Depressive Disorders” Audiovisual Presentation at the University of Arizona Annual Women’s Mental Health Symposium. January, 2004, Tucson, Arizona.

“Genes and Their Brains”. Audiovisual Presentation at the 12th Annual Psychopharmacology Review Conference, February 2004, Tucson, Arizona.

“Frontier Research on Electrically Based Interventions in Psychiatric Treatment”. Audiovisual Presentation at the 12th Annual Psychopharmacology Review Conference, February 2004, Tucson, Arizona.

“Update in the Treatment of Anxiety Disorders”. Audiovisual Presentation at the 12th Annual Psychopharmacology Review Conference, February 2004, Tucson, Arizona.

“Carnitine levels in psychiatric patients treated chronically with valproic acid” Poster presentation at the Biological Psychiatry Annual Meeting, May 2004, New York, New York.

“Carnitine levels in psychiatric patients treated chronically with valproic acid”. Audiovisual Presentation at the NCDEU Annual Meeting, June 2004, Phoenix, Arizona.

“Safety, tolerability, and Efficacy of Psilocybin in Patients with Treatment Resistant Obsessive-compulsive Disorder” Poster presentation at the NCDEU Annual Meeting, June 2004, Phoenix, Arizona.

“Monoamine Related Genes in Association with Major Depression” Poster presentation at the Annual Meeting of the American College of Neuropsychopharmacology, Dec 2004, San Juan, Puerto Rico.

“Risk of Depression” Audiovisual Presentation at the University of Arizona Annual Women’s Mental Health Symposium. January, 2005, Tucson, Arizona.

- “Genes and Their Brains”*. Audiovisual Presentation at the 13th Annual Psychopharmacology Review Conference, February 2005, Tucson, Arizona.
- “Frontier Research on Electrically Based Interventions in Psychiatric Treatment”*. Audiovisual Presentation at the 13th Annual Psychopharmacology Review Conference, February 2005, Tucson, Arizona.
- “Update in the Treatment of Anxiety Disorders”*. Audiovisual Presentation at the 13th Annual Psychopharmacology Review Conference, February 2005, Tucson, Arizona.
- “Monoamine Related Genes in Association with Major Depression”* Poster presentation at the Annual Meeting of the Society of Biological Psychiatry, May 2005, Atlanta, Georgia.
- “Role of Medications and Resilience”* Arizona Mental Health Association Public Symposium. November 2005, Phoenix, Arizona.
- “Risk of Depression”* Audiovisual Presentation at the University of Arizona Annual Women’s Mental Health Symposium. January, 2006, Tucson, Arizona.
- “Neurobiology of Depression: Insights from neurotransmitter depletions studies.”* Psychiatry Grand Rounds Presentation at State University of New York, Upstate Medical University. February 2006, Syracuse, New York.
- “Treatment Resistant Depression: Novel Treatment Approaches.”* Psychiatry Grand Rounds Presentation at University of New Mexico School of Medicine. February 2006, Albuquerque, New Mexico.
- “Genes and Their Brains”*. Audiovisual Presentation at the 14^h Annual Psychopharmacology Review Conference, February 2006 Tucson, Arizona.
- “Frontier Research on Electrically Based Interventions in Psychiatric Treatment”*. Audiovisual Presentation at the 14^h Annual Psychopharmacology Review Conference, February 2006 Tucson, Arizona.
- “Update in the Treatment of Anxiety Disorders”*. Audiovisual Presentation at the 14^h Annual Psychopharmacology Review Conference, February 2006 Tucson, Arizona.
- “Clinical Research with Psilocybin”*. Grand Rounds Presentation at University of Texas Health Sciences Center, San Antonio. March, 2006, San Antonio, Texas.
- “Psilocybin for Obsessive Compulsive Disorder”*. Hot Topics Presentation at the Annual Meeting of the West Coast College of Biological Psychiatry. April, 2006, Costa Mesa, California.
- “Cerebrospinal Fluid Monoamine Metabolites during Tryptophan Depletion”* Poster Presentation at the Annual Meeting of the West Coast College of Biological Psychiatry. April, 2007, Tucson, Arizona.

- "Vagus Nerve Stimulation, Mechanism of Action"*. Audiovisual Presentation at the Venezuelan College of Neuropsychopharmacology. November, 2007.
- "Tryptophan Depletion as predictor of outcome"* Audiovisual Presentation at the Annual Meeting of the West Coast College of Biological Psychiatry. April, 2008, Los Angeles, California.
- "The Pharmacokinetics of Sertraline Across Pregnancy And Postpartum"*. Poster presentation at the NCDEU Annual Meeting, June 2008, Phoenix, Arizona.
- "Endophenotypes in Psychiatry"* Pediatrics Research Grand Rounds, October, 2008.
- "Molecular Basis of Psychopharmacology"*. Audiovisual Presentation at the 17^h Annual Psychopharmacology Review Conference, February 2009 Tucson, Arizona.
- "Treatment Resistant Depression: Current Management Strategies"*. Audiovisual Presentation at the 17^h Annual Psychopharmacology Review Conference, February 2009 Tucson, Arizona.
- "Update in the Treatment of Anxiety Disorders"*. Audiovisual Presentation at the 17^h Annual Psychopharmacology Review Conference, February 2009 Tucson, Arizona.
- "Genetics of Depression, role in vulnerability and treatment"* Audiovisual Presentation at the University of Arizona Annual Women's Mental Health Symposium. April, 2009, Tucson, Arizona.
- "Depression Biology and Treatment"* Audiovisual Presentation at the University of Arizona's 8th Annual Women's Mental Health Symposium. April, 2008, Tucson, Arizona.
- "Obsessive Compulsive Disorder Update"*. Audiovisual Presentation at the 14^h Annual Santa Fe Psychiatric Symposium, February 2009 Santa Fe, New Mexico.
- "Is Tryptophan Depletion a Phenotype for Depression?"* Audiovisual Presentation at the Psychiatry Research Society Annual Meeting. February, 2010, Park City, Utah.
- "Molecular Basis of Psychopharmacology"*. Audiovisual Presentation at the 18^h Annual Psychopharmacology Review Conference, February 2010 Tucson, Arizona.
- "PTSD, OCD, and Other Anxiety Disorders"*. Audiovisual Presentation at the 18^h Annual Psychopharmacology Review Conference, February 2010 Tucson, Arizona.

- “Association of SLC6A4 and Depressive Response to Tryptophan Depletion: A replication”*. Poster Presentation at the Annual Meeting of the Society of Biological Psychiatry, May 2010, New Orleans LA.
- “Border Mental Health”* Audiovisual Presentation at Hispanic Serving Health Professions Schools Symposium, Stanford University. July, 2010, Palo Alto, CA.
- “Association of SLC6A4 and Depressive Response to Tryptophan Depletion: A replication”*. Poster Presentation at the Annual Meeting of the International Society of Psychiatric Genetics, October 2010, Athens Greece.
- “Telepsychiatry Along the Border”* Audiovisual Presentation at the Annual Meeting of the Arizona Psychological Association. October 2010, Tucson, AZ.
- “Molecularly Informed Diagnosis and Treatment for Depression and Anxiety Disorders”* Audiovisual Presentation at Frontiers in Medical Research, University of Arizona College of Medicine. November, 2010, Tucson, AZ.
- “Use of Standard Webcam Equipment in the Treatment of Hispanic Immigrants with Depression”* Audiovisual Presentation at Psychiatry Grand Rounds, University of Arizona College of Medicine. February, 2011, Tucson, AZ.
- “Obsessive Compulsive Disorder Treatment Update”*. Audiovisual Presentation at the 19th Annual Psychopharmacology Review Conference, February 2011 Tucson, Arizona.
- “Treatment Resistant Depression”* Audiovisual Presentation at the University of Arizona’s 10th Annual Women’s Mental Health Symposium. March, 2011, Tucson, Arizona.
- “Diversity: Threading the Needle Between Federal Affirmative Action Mandates and State Constitutional Amendments in Four States”*. Audiovisual Presentation at the AAMC Spring Meeting of GRMC/GDI. March 2011, New Orleans, Louisiana.
- “Anxiety Response During Tryptophan Depletion and Association with SLC6A4”*. Audiovisual Presentation at the World Psychiatric Association Annual Meeting, September 2012, Buenos Aires, Argentina.
- “Fixed and Varying Levels of Ability in Academic Medicine”*. Audiovisual Presentation at the AAMC Annual Meeting. November 2011, Denver, Colorado
- “Obsessive Compulsive Disorder Treatment Update”*. Audiovisual Presentation at the 20th Annual Psychopharmacology Review Conference, February 2012 Tucson, Arizona.
- “Obsessive Compulsive Spectrum”* Audiovisual Presentation at the University of Arizona’s 11th Annual Women’s Mental Health Symposium. April, 2012, Tucson, Arizona.

“Anxiety Disorders Overview”. Audiovisual Presentation at the 21st Annual Psychopharmacology Review Conference, February 2013 Tucson, Arizona.

“Molecular Basis of Psychopharmacology”. Audiovisual Presentation at the 21st Annual Psychopharmacology Review Conference, February 2013 Tucson, Arizona.

“Mental Health Along the US-Mexico Border”. Dean’s Diversity Series, Texas Tech University School of Medicine, June 2013 El Paso, Texas.

GRANTS AND CONTRACTS

NIH Current

1 RO1 CA133081-01A1, “Emotion Regulation and Depression in Breast Cancer Survivorship”

Principal Investigators: **Annette Stanton, Ph.D., and Karen Weihs, M.D.**

% Effort 5% Total Budget \$3,496,315

Dates of Project: 7/01/09 - 06/30/14

NIH Past

1 R01 MH073712-01A2 “Vulnerability to Stress-Induced Depression Post Job Loss”

Principal Investigator: George W. Howe, Ph.D. **Role: Co-Investigator**

% Effort 5%

Dates of Project: 07/01/06 - 06/30/10

1 R01 MH066235-01A1 “Tryptophan Depletion: A Phenotypic Marker for Depression”

Principal Investigator: **Francisco A. Moreno, M.D.**

% Effort 50% Total Budget \$2,291,564

Dates of Project: 4/01/03 - 3/31/08 (No Cost Extension through 03-09)

1R01 MH066902-01A2 “Trait and State Frontal Brain Asymmetry in Depression”

Principal Investigator: John Allen, Ph.D. **Role: Co-Investigator**

% Effort 10%

Dates of Project: 04/01/04 - 03/30/09

1 RO3 MH57364-01A1, “Tryptophan Depletion and CSF Monoamine Metabolites”

Principal Investigator: **Francisco A. Moreno, M.D.**

% Effort 20% Total Budget \$149,887

Dates of Project: 4/01/98 - 09/30/00

RO1 MH54648, “Serotonin Function and Vulnerability to Depression”

Principal Investigator: Pedro L. Delgado, M.D.

Role: Co-Investigator

% Effort 15% Total Budget \$824,682

Dates of Project: 07/01/97 - 06/30/01

2 R01 MH48977 “Mechanisms of Antidepressant Action”

Principal Investigator: Pedro L. Delgado, M.D.

Role: Co-Investigator

% Effort 15% \$1,286,290

Dates of Project: 07/01/00 - 06/30/01

R01 MH56965 “Acupuncture in the Treatment of Depression”

Principal Investigator: John Allen, Ph.D.

Role: Consulting Psychiatrist

% Effort 10% starting 02/98

Dates of Project: 09/30/97 - 04/30/02

Private Foundation Past

Robert Wood Johnson Foundation. “Telepsychiatry for the Treatment of Underserved Hispanics with Depression”

Principal Investigator: **Francisco A. Moreno, M.D.**

% Effort 20% starting 05/08

Dates of Project: 05/01/08 - 04/30/10, NCE to 06-30-09

Arizona Institute for Mental Health Research. “Association of Monoamine Systems Genes and Depression”

Principal Investigator: **Francisco A. Moreno, M.D.**

No salary support (\$25,000 for one year)

Hefter Research Institute. “Effects of Psilocybin in patients with treatment resistant OCD”

Principal Investigator: **Francisco A. Moreno, M.D.**

% Effort 5% starting 9/01 \$54,000

Dates of Project: 07/01 to 12/04

Multidisciplinary Association for Psychedelic Studies. “Effects of Psilocybin in patients with treatment resistant OCD”

Principal Investigator: **Francisco A. Moreno, M.D.**

No salary support

College of Medicine

Dean’s Physician-Scientist Career Development Award

Principal Investigator: **Francisco A. Moreno, M.D.**

% Effort 50% max. \$50,000/yr

Dates of Project: 07/01/98 - 06/30/00

Investigator Initiated Collaborations with Industry Contracts (Excluding clinical trial contracts)

Cyberonics Inc. “A candidate gene approach to the study of treatment resistant depression and the therapeutic response to Vagus Nerve Stimulation (VNS) with the Neurocybernetic Prosthetic Device (NCP®)

Principal Investigator: **Francisco A. Moreno, M.D.**

% Effort 10% starting 9/01 \$43,200

Dates of Project: 07/01 to 06/02

Cyberonics Inc. “Cerebrospinal fluid neurochemicals during VNS with NCP”. (Three site study)

Principal Investigator: **Francisco A. Moreno, M.D.**

% Effort 5% starting 05/01 (Budgeted per patient/procedure) \$19,620

Dates of Project: 07/01 to 06/02

Sigma Tau. “Carnitine levels in divalproex treated psychiatric patients”.

Principal Investigator: **Francisco A. Moreno, M.D.**

% Effort 5% starting 08/02 \$26,789

Dates of Project: 08/02 to 06/03

Cyberonics, “A Long-Term, Prospective, Multicenter Study to Compare the Clinical, Quality of Life, and Health Care Utilization Outcomes of the NeuroCybernetic Prosthesis (NCP) System to the Standard of Care Treatment in Patients with Depression.”

Principal Investigator: **Francisco A. Moreno, M.D.**

Total Cost: \$76,080

Period of Support: 05-10-01 to 08-15-03

This is a true and accurate statement of my activities and accomplishments. I understand that misrepresentation in securing continuing status and promotion may lead to dismissal or suspension under ARBOR Policy 6-201 I. l. b.

Revised July 2013

Francisco A. Moreno, M.D.